Opthea Limited (ASX:OPT)
0.6000
0.00 (0.00%)
Mar 14, 2025, 4:10 PM AEST
Opthea Revenue
In the fiscal year ending June 30, 2025, Opthea had annual revenue of $146.00K USD, down -44.27%. Opthea had revenue of $-3.00K in the half year ending June 30, 2025, a decrease of -101.59%.
Revenue
$146.00K
Revenue Growth
-44.27%
P/S Ratio
3,317.43
Revenue / Employee
$4.42K
Employees
33
Market Cap
738.77M AUD
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 146.00K | -116.00K | -44.27% |
| Jun 30, 2024 | 262.00K | -123.28K | -32.00% |
| Jun 30, 2023 | 385.28K | 186.27K | 93.60% |
| Jun 30, 2022 | 199.01K | 103.44K | 108.24% |
| Jun 30, 2021 | 95.56K | -5.13K | -5.09% |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| CSL Limited | 23.73B |
| Ramsay Health Care | 17.79B |
| Sonic Healthcare | 9.65B |
| Ansell | 3.06B |
| Cochlear | 2.34B |
| Regis Healthcare | 1.16B |
| Telix Pharmaceuticals | 1.01B |
| Neuren Pharmaceuticals | 218.86M |
Opthea News
- 17 days ago - Opthea Appoints Hamish George As CFO - Nasdaq
- 3 months ago - Opthea Provides Corporate Update - GlobeNewsWire
- 5 months ago - ASX 200 LIVE: Sharemarket falls; Soul Patts, Brickworks in tie-up; Trump hikes steel tariffs; Washington, Beijing trade tensions in focus - The Australian Financial Review
- 7 months ago - ASX 200 LIVE: Trump tariffs; sharemarket drops 1pc on Wednesday, iron ore slumps; US equities fall on escalating US-China trade war - The Australian Financial Review
- 8 months ago - Phil King’s Regal writes Opthea to zero and backs off risky bets - The Australian Financial Review
- 8 months ago - Opthea (OPT) Halts Key Trials Following Disappointing Results - GuruFocus
- 8 months ago - Opthea in active talks with funders after second trial fails - The Australian Financial Review
- 8 months ago - Opthea Announces Decision to Discontinue Wet AMD Trials - GlobeNewsWire